IPSC

Century Therapeutics Stock Analysis

AI Rating

Neutral
  • Quality1/10
  • Growth↑ 8/10
  • Value↓ 2/10
Century Therapeutics sales and earnings growth
IPSC Growth
Good
  • Revenue Y/Y↑ 1556.76%
  • EPS Y/Y↑ 91.30%
  • FCF Y/Y↑ 5.05%
Century Therapeutics gross and profit margin trends
IPSC Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -8.80%
  • ROIC 5Y↓ -26.41%
Century Therapeutics net debt vs free cash flow
IPSC Risk
Great
  • Debt / Equity↓ 0.3
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Century Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks